Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165344 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP3A4 | |
| SCHEMBL444362 | 0.81 | APLNR (0.41) | — | |
| SCHEMBL441906 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CYP3A4 | |
| SCHEMBL6558019 | 0.75 | ALDH1A1 (0.31) | ALDH1A1CYP3A4 | |
| SCHEMBL12019112 | 0.73 | ALDH1A1 (0.65) | ALDH1A1CYP3A4 | |
| SCHEMBL2254659 | 0.71 | ALDH1A1 (0.49) | ALDH1A1CYP3A4 | |
| SCHEMBL2049404 | 0.71 | ALDH1A1 (0.44) | ALDH1A1CYP3A4 | |
| SCHEMBL3197954 | 0.68 | ALDH1A1 (0.59) | ALDH1A1CYP3A4 | |
| SCHEMBL15647857 | 0.68 | MMP2 (0.32) | — | |
| SCHEMBL1486693 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108969-A | Efficient and migration-resistant antioxidant as well as preparation method and application thereof | 华南理工大学 | 2022-09-27 | — | — | CN | claimed |
| US-8138268-B2 | Adhesive composition, circuit connecting material, connecting structure for circuit member, and semiconductor device | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2012-03-20 | — | — | US | claimed |
| CN-115108969-A | Efficient and migration-resistant antioxidant as well as preparation method and application thereof | 华南理工大学 | 2022-09-27 | — | — | CN | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8309658-B2 | Adhesive composition, circuit connecting material, connecting structure for circuit member, and semiconductor device | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8138268-B2 | Adhesive composition, circuit connecting material, connecting structure for circuit member, and semiconductor device | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20120063109-A1 | ADHESIVE COMPOSITION, CIRCUIT CONNECTING MATERIAL, CONNECTING STRUCTURE FOR CIRCUIT MEMBER, AND SEMICONDUCTOR DEVICE | RESONAC CORPORATION (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2011103111-A1 | METHOD OF TREATING DISEASE INVOLVING MYELIN AND/OR AXONAL LOSS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110176288-A1 | ADHESIVE COMPOSITION, CIRCUIT CONNECTING MATERIAL, CONNECTING STRUCTURE FOR CIRCUIT MEMBER, AND SEMICONDUCTOR DEVICE | HITACHI CHEMICAL COMPANY LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2246400-A1 | Circuit connecting material | Hitachi Chemical Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| EP-1754762-A1 | ADHESIVE COMPOSITION, CIRCUIT CONNECTING MATERIAL, CONNECTING STRUCTURE FOR CIRCUIT MEMBER, AND SEMICONDUCTOR DEVICE | Hitachi Chemical Co., Ltd. (JP) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885CYP3A4 3900/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885CYP3A4 3900/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885CYP3A4 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.